Mesa Labs loses key customer Sema4; orders to drop starting Q3 FY2023

MESA LABORATORIES INC /CO/

Sema4 exiting reproductive health screening; will significantly reduce consumables orders starting Q3 FY2023.
Without Sema4, Clinical Genomics ex-COVID revenues would have been ~$56.3M vs $64.5M over prior 12 months.
Sema4 products generated significantly higher gross profit percentage than overall Clinical Genomics business.
Mesa has no other material revenues for expanded carrier screening with other customers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.